Acutus Medical, Inc. (AFIB)
NASDAQ: AFIB · IEX Real-Time Price · USD
0.162
-0.001 (-0.86%)
At close: Apr 26, 2024, 9:41 AM
0.167
+0.005 (2.78%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Acutus Medical Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Acutus Medical.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Acutus Medical.
Recommendation Trends
| Rating | Mar '22 | Apr '22 | May '22 | Jun '22 | Jul '22 | Aug '22 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 2 | 2 | 2 | 2 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $1 → $1.5 | Hold | Maintains | $1 → $1.5 | +825.93% | Aug 16, 2022 |
| BTIG | BTIG | Strong Buy Maintains $2 → $1.5 | Strong Buy | Maintains | $2 → $1.5 | +825.93% | Jun 24, 2022 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $2 | Hold → Strong Buy | Upgrades | $2 | +1,134.57% | Apr 27, 2022 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $5 → $1 | Hold | Maintains | $5 → $1 | +517.28% | Apr 14, 2022 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 20, 2022 |
Financial Forecast
Revenue This Year
32.49M
from 7.16M
Increased by 353.50%
Revenue Next Year
50.45M
from 32.49M
Increased by 55.27%
EPS This Year
-1.81
from -2.81
EPS Next Year
-1.43
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 37.1M | 59.3M |
| Avg | 32.5M | 50.4M |
| Low | 29.3M | 41.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 418.2% | 82.6% |
| Avg | 353.5% | 55.3% |
| Low | 309.0% | 27.9% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -1.44 | -0.96 |
| Avg | -1.81 | -1.43 |
| Low | -2.15 | -1.85 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.